NCI OA Special Notice of Subcontract Opportunity at the Frederick National Laboratory for Cancer Research”

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NIH NCI

Contract Value

Not provided

Codes & Classification
Solicitation Number

-

NAICS

-

Classification Code

-

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
Documents1
This Special Notice, issued by the National Cancer Institute (NCI) under the Department of Health and Human Services, serves to inform the public of a forthcoming subcontract opportunity at the Frederick National Laboratory for Cancer Research (FNLCR). The FNLCR, a Government-Owned Contractor-Operated Federally Funded Research and Development Center (FFRDC) located at Fort Detrick, Maryland, is currently operated by Leidos Biomedical Research, Inc. (Leidos Biomed) under Prime Contract No. 75N91019D00024 & HHSN261201500003I. The laboratory is dedicated to accelerating the translation of laboratory research into innovative diagnostic tests and treatments for cancer and AIDS, in collaboration with academic, governmental, and corporate partners. This notice is issued strictly for informational purposes in accordance with FAR 15.201(d) and does not constitute a formal solicitation, invitation for bid, or request for proposal. No offers are being solicited at this time, and any information submitted in response will become government property without the expectation of return, discussion, or debriefing. Interested parties are advised to monitor the referenced sites for future business opportunities related to the FNLCR. The scope of the anticipated subcontract centers on supporting the Pamoja Tulinde Maisha (PALM) clinical research program, which was established in response to the 2018 Ebola outbreak in the Democratic Republic of the Congo (DRC). This program is a collaborative effort between the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID), Leidos Biomed, and the DRC’s National Institute of Biomedical Research. The PALM program’s mission is to provide a robust clinical research platform to advance understanding and treatment of infectious diseases in the region. Key requirements for the subcontractor include: - Provision of core clinical infrastructure and services necessary for conducting human subjects research. This encompasses support for multiple research sites, laboratories, biorepository operations, pharmacy cold chain management, data management, supply chain depots, and administrative/operations offices. - Support for the biorepository, including processing, tracking, storage, and transfer of biospecimens collected during PALM clinical research, as well as management of outbreak samples. - Direct support for clinical research protocols, specifically: - PALM 004: An immunologic sub-study focused on characterizing immune responses to Bundibugyo virus disease and their associations with clinical outcomes, conducted at four treatment centers in Eastern DRC and one research site in Kinshasa for healthy volunteer recruitment. - PALM 011: An observational cohort study of patients treated for mpox virus disease at two rural hospital sites in the DRC. The intended outcome of this subcontract is to ensure the sustained operation and advancement of clinical research infrastructure in the DRC, thereby facilitating high-quality research into emerging infectious diseases and supporting the global health mission of the NIH and its partners. The contracting entity for this opportunity is the NIH NCI, with Leidos Biomedical Research, Inc. serving as the prime contractor responsible for operations and technical support at FNLCR. The primary point of contact for interested parties is Heather Sewell, Lead Subcontracts Administrator, who can be reached at [email protected]. Interested organizations should express their interest by 5:00 PM ET on Friday, November 20, 2026. This notice does not specify any set-aside requirements or special procurement considerations. Contractors evaluating this opportunity should note that it is not a solicitation and that no immediate contracting action will result from responses to this notice. However, it provides valuable insight into the anticipated scope of work and the strategic priorities of the FNLCR and its partners, allowing potential subcontractors to assess alignment with their capabilities and prepare for future solicitations. For further details and updates, contractors are encouraged to visit the official notice page on SAM.gov at https://sam.gov/opp/463c4c2f23bb43979b7adbfcc25e3b7e/view.